Stigmatizing Attitudes Towards People With PD Using The Parkinson’s Disease Social Stigma Perception Scale (PDSP): A Nationwide Study
Objective: This study aimed to: 1) identify factors associated with stigma towards people living with Parkinson's Disease (PwP), and 2) analyze sociodemographic-based variations in the…WATCH-PD Qualitative Study: A Mental Model of Coping with Disease Progression
Objective: To qualitatively evaluate how individuals’ adjust to and cope with symptoms of Parkinson’s disease (PD). Background: The WATCH-PD qualitative study is evaluating meaningful symptoms…Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson’s disease.
Objective: This study aimed to determine whether people with Parkinson’s disease (PD) with an active lifestyle had increased production of certain microbial metabolites such as…Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON
Objective: The EPSILON study aimed to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa/dopa decarboxylase inhibitor (DDCi) in patients with…AccessPD Registry Update: Accelerating Parkinson’s Disease Research Through Integrated Digital Solutions
Objective: To update on AccessPD's progress, emphasising the growth in patient recruitment, data integration, and the preliminary analysis aimed at advancing Parkinson's disease (PD) research.…A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler
Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…Estimating the Proportion of Parkinson’s Disease Clinical Trial Subjects Who Showed No Measurable MDS-UPDRS Motor Score Progression Over 1 Year
Objective: To determine what percentage of subjects with early Parkinson’s disease demonstrated no measurable worsening of MDS-UPDRS motor scores over 52 weeks in a Phase…LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics
Objective: To evaluate safety and biomarker effects of BIIB122/DNL151 in participants with pathogenic LRRK2 variants diagnosed with Parkinson’s disease (LRRK2-PD). Background: Increased LRRK2 kinase activity…Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial
Objective: To investigate synaptic loss in Parkinson's Disease depression (PDd) using PET and [11C]UCB-J (a marker for synaptic density) and present the initial blinded findings…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 436
- Next Page »